With faciliites and personnel in Dallas, TX and in Austin, TX., and still a firm in development stage, Berkshire Biomedical Corporation is a privately-held medical device company structured around pioneering use of biometric technologies, combined with cloud-based and physician-enabled remote management systems with intent to provide precise and accurate personalized medication delivery only to Authenticated Intended User (AIU). Still under development and NOT available for in-use activity and usage, the Companys lead product -- Computerized Oral Prescription Administration System (COPA) - is a hand-held, automated, personalized oral liquid dispensing system. The System is designed and intended to deliver controlled and non-controlled liquid oral medications ONLY to Authenticated Intended User upon confirmation of dual biometric identifications (fingerprint and dentition). Upon receiving regulatory authorization, the Company intends to initially seek opportunities to leverage COPA in the delivery and remote management of oral liquid medication methadone, for Medication Use for Opioid Use Disorder treatment (MOUD) and then subsequently for the delivery of controlled medications for the treatment of pain, as they have the greatest need for the benefits of COPAs features.
